26 May 2013
Keywords: GlaxoSmithKline, XenoPort, Horizant, Pozenm Restless legs syndrome, GI, Phase III,
Article | 08 November 2010
UK pharma giant GlaxoSmithKline (LSE: GSK) and partner XenoPort (Nasdaq: XNPT) said on Friday that the US Food and Drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 November 2010
9 November 2010
24 May 2013
© 2013 thepharmaletter.com